Researchers analyzed data from 20 previous observational studies involving over 245,000 adults. They looked at the connection between a blood test marker called the Atherogenic Index of Plasma (AIP) and metabolic-associated fatty liver disease (MAFLD/NAFLD). AIP is a simple calculation based on cholesterol and triglyceride levels already measured in standard blood tests.
The analysis found that people with fatty liver disease had significantly higher AIP levels than those without the condition. Having an elevated AIP was associated with about three times higher odds of having fatty liver disease. The marker showed moderate accuracy for identifying the condition, but it was not perfect.
This research is based on observational studies, which can only show a link, not prove that high AIP causes fatty liver disease. The findings suggest AIP could be a helpful, simple clue for doctors to consider during early screening, especially for people already at risk for heart and metabolic problems. Readers should understand this is a promising research finding, not a new diagnostic test ready for routine use.